References | Country | No. of Patients (RF/Control) | Treatment Gender (M/F) | Control Gender (M/F) | Mean age (years) (RF/Control) | Kellgren-Lawrence grade | BMI (RF/Control) | Disease courses (years) (RF/Control) | Treatment pain score baseline | Control pain score baseline |
---|---|---|---|---|---|---|---|---|---|---|
[21] | Korea | 17/18 | 2/15 | 3/15 | 67.9/66.5 | NA | 26.2/26.5 | 6.3/7.4 | 7.82 (1.38) | 7.72 (0.75) |
[22] | China | 17/19 | NA | NA | NA | 1–3 | NA | NA | 7.26 (1.34) | 7.19 (1.57) |
[23] | Iran | 24/26 | 11/13 | 10/16 | 57.0/60.6 | 3–4 | NA | NA | 7.08 (1.41) | 7.11 (1.03) |
[24] | China | 31/31 | NA | NA | NA | NA | NA | NA | 7.25 (1.33) | 7.21 (1.58) |
[25] | China | 27/27 | 7/20 | 9/18 | 62.2/62.4 | 2–4 | NA | 5.01/4.96 | 7.12 (1.08) | 7.14 (1.03) |
[35] | China | 12/12 | 5/7 | 3/9 | 51.7/54.0 | 1–3 | NA | NA | 8.25 (0.62) | 8.16 (0.72) |
[26] | Turkey | 37/36 | 7/30 | 9/25 | 64.0/64.0 | 2–3 | 23.5/22.9 | 5/5 | NA | NA |
[27] | China | 45/47 | 17/28 | 20/27 | 66.1/65.9 | NA | 24.5/24.9 | 8.2/8.2 | 6.53 (1.10) | 6.38 (1.03) |
[28] | China | 49/47 | 12/37 | 11/36 | 56.5/61.5 | 3–4 | NA | 3.04/2.96 | 7.3 (1.2) | 7.3 (1.4) |
[29] | Egypt | 30/30 | 9/21 | 12/18 | 62.0/56.9 | 2–4 | 32.0/30.2 | 7.6/5.7 | 7.07 (0.2) | 7.07 (0.2) |
[30] | America | 76/75 | 26/50 | 26/49 | 63.0/66.0 | 3–4 | 30.6/30.4 | 10.7/8.6 | 7.3 (1.2) | 7.2 (1.0) |
[31] | UK | 15/15 | 6/9 | 6/9 | 63.0/63.0 | 2–4 | 31.0/31.0 | 5.6/4.3 | 6.3 (1.2) | 5.8 (1.2) |
[32] | America | 89/88 | 37/52 | 34/54 | 63.3/63.1 | 2–3 | 32.2/30.5 | 7.5/8.8 | NA | NA |
[33] | China | 26/27 | 10/16 | 12/15 | 59.5/60.9 | 3–4 | 24.6/25.8 | 2.7/2.9 | 6.46 (1.14) | 6.37 (0.93) |
[34] | Italy | 8/8 | 2/6 | 3/5 | 70.4/70.9 | NA | 29.5/29.6 | 9.6/10.4 | 8.25 (0.70) | 8.0 (1.19) |